TY - JOUR
T1 - Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer
T2 - Data from the Alliance Z11102 Study
AU - Rosenkranz, Kari M.
AU - Ballman, Karla
AU - McCall, Linda
AU - McCarthy, Colleen
AU - Kubicky, Charlotte D.
AU - Cuttino, Laurie
AU - Hunt, Kelly K.
AU - Giuliano, Armando
AU - Van Zee, Kimberly J.
AU - Haffty, Bruce
AU - Boughey, Judy C.
N1 - Funding Information:
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award nos. U10CA180821 and U10CA180882; UG1CA233290, UG1CA233329, and UG1CA232760. Dr. Karla Ballman discloses an NCI grant to the Alliance Cooperative Cancer Trial group. Dr. Kelly Hunt discloses a Medical Advisory Board role for Armada Health and Merck & Co., and also disclosures research funding to her institution from Armada Health, Merck & Co., Endomagnetics, Lumicell, and OncoNano. Dr. Armando Giuliano discloses an Alliance grant. Dr. Judy Boughey discloses funding from the NCI to Alliance for Clinical Trials in Oncology group for travel to Alliance meetings. All other authors had no disclosures. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. https://acknowledgments.alliancefound.org .
Publisher Copyright:
© 2020, Society of Surgical Oncology.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Background: Diagnoses of multiple ipsilateral breast cancer (MIBC) are increasing. Historically, the primary treatment for MIBC has been mastectomy due to concerns about in-breast recurrence risk and poor cosmetic outcome. The Alliance Z11102 study prospectively assessed cosmetic outcomes in women with MIBC treated with breast-conserving therapy (BCT). Patients and Methods: Z11102 was a multicenter trial enrolling women with two or three separate sites of biopsy-proven malignancy separated by ≥ 2 cm within the same breast. Cosmetic outcome was a planned secondary endpoint. Data were collected with a four-point cosmesis survey (1 = excellent, 4 = poor) and the BREAST-Q (scored 0–100). All patients undergoing successful breast-conserving therapy were treated with whole-breast radiation. Associations were assessed with Chi square or Fisher’s exact tests as appropriate. Results: Cosmetic outcome data for 216 eligible women who completed therapy are included in this analysis. Of the 136 patients who completed the survey 2 years postoperatively, 70.6% (N = 96) felt the result was good or excellent, while 3.7% (N = 5) felt the result was poor. We found no significant differences in patient-reported cosmetic outcomes when stratifying by patient age, number of lesions (two or three), number of incisions, number of lumpectomies, or size of largest area of disease. Mean satisfaction score on the BREAST-Q was 77.2 at 6 months following whole-breast radiation and 73.7 at 3 years following surgery. Conclusions: BCT performed for MIBC results in good or excellent cosmesis for the majority of women. From a cosmetic perspective, BCT is a valid surgical approach to women with MIBC. Trial registration: ClinicalTrials.gov Identifier: NCT01556243.
AB - Background: Diagnoses of multiple ipsilateral breast cancer (MIBC) are increasing. Historically, the primary treatment for MIBC has been mastectomy due to concerns about in-breast recurrence risk and poor cosmetic outcome. The Alliance Z11102 study prospectively assessed cosmetic outcomes in women with MIBC treated with breast-conserving therapy (BCT). Patients and Methods: Z11102 was a multicenter trial enrolling women with two or three separate sites of biopsy-proven malignancy separated by ≥ 2 cm within the same breast. Cosmetic outcome was a planned secondary endpoint. Data were collected with a four-point cosmesis survey (1 = excellent, 4 = poor) and the BREAST-Q (scored 0–100). All patients undergoing successful breast-conserving therapy were treated with whole-breast radiation. Associations were assessed with Chi square or Fisher’s exact tests as appropriate. Results: Cosmetic outcome data for 216 eligible women who completed therapy are included in this analysis. Of the 136 patients who completed the survey 2 years postoperatively, 70.6% (N = 96) felt the result was good or excellent, while 3.7% (N = 5) felt the result was poor. We found no significant differences in patient-reported cosmetic outcomes when stratifying by patient age, number of lesions (two or three), number of incisions, number of lumpectomies, or size of largest area of disease. Mean satisfaction score on the BREAST-Q was 77.2 at 6 months following whole-breast radiation and 73.7 at 3 years following surgery. Conclusions: BCT performed for MIBC results in good or excellent cosmesis for the majority of women. From a cosmetic perspective, BCT is a valid surgical approach to women with MIBC. Trial registration: ClinicalTrials.gov Identifier: NCT01556243.
UR - http://www.scopus.com/inward/record.url?scp=85088465542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088465542&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-08893-w
DO - 10.1245/s10434-020-08893-w
M3 - Article
C2 - 32699926
AN - SCOPUS:85088465542
SN - 1068-9265
VL - 27
SP - 4650
EP - 4661
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 12
ER -